Athira Pharma, Inc. (ATHA) Dividend History

Athira Pharma, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases, including Alzheimer's disease. Founded with the goal of addressing the underlying causes of neurodegeneration, the company leverages its proprietary small molecule platform to discover and develop novel treatments aimed at restoring neuronal health and function.

18706 North Creek Parkway, Suite 104, Bothell, WA, 98011
Phone: (425) 620-8501
Website: https://www.athira.com

Dividend History

Athira Pharma, Inc. currently does not pay dividends

Company News

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

Athira Pharma announced positive results from a Phase 1 clinical trial of its drug candidate ATH-1105 in healthy volunteers, supporting continued development for the potential treatment of amyotrophic lateral sclerosis (ALS). The company plans to initiate a clinical trial in ALS patients in late 2025.

GlobeNewswire Inc.
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up - Zacks Investment Research

Athira Pharma has dosed the last patient in the phase II/III LIFT-AD study evaluating its pipeline candidate, fosgonimeton, for the treatment of mild-to-moderate Alzheimer's disease. The study is designed to assess the treatment effects of fosgonimeton across multiple aspects of the disease.

Zacks Investment Research

Featured Companies: ACRV ADPT RAPT
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones index closed lower by around 20 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Retractable Technologies The Trade: Retractable Technologies, Inc. (NYSE: RVP) President and CEO Thomas J Shaw acquired a total of 3,455 shares an average price of $1.07. To acquire these shares, it cost around $3,703. What’s Happening: On Nov. 14, Retractable Technologies reported that its loss from operations was $8.7 million for the first ...

Benzinga

Featured Companies: GSAT RVP
Dow, S&P 500 end lower after Powell says Fed isn't trying to provoke a recession

U.S. stock indexes end lower Wednesday, giving back earlier gains, after Federal Reserve Chairman Jerome Powell reiterated plans for combating inflation, in Capitol Hill testimony.

MarketWatch

Featured Companies: CHEF COMP DJIA DOW MO
Why Athira Pharma Stock Imploded Today

Its mid-stage clinical trial failed to help patients with Alzheimer's.

The Motley Fool

Page data last updated 07/23/2025 02:19:46 UTC